U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment:: description was created based on several sources, including, http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdf

Bleomycin is a mixture of cytotoxic glycopeptide antibiotics isolated from a strain of Streptomyces verticillus. Bleomycin has antitumor activity. Bleomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Bleomycin has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2. The antibiotic antitumor drugs are cell cycle-nonspecific except for Bleomycin (which has major effects in G2 and M phases).

CNS Activity

Curator's Comment:: Bleomycin does not cross the blood-brain barrier.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
PubMed

PubMed

TitleDatePubMed
Biochemical effects of bleomycin A2 on Novikoff hepatoma ascites cells.
1975
Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma.
1988 Sep
Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer.
1989 Oct
Dysregulation of apoptosis by c-myc in transgenic hepatocytes and effects of growth factors and nongenotoxic carcinogens.
1999 Aug
Nucleic Acid recognition by metal complexes of bleomycin.
1999 Sep 8
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.
2000 May
Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis.
2001 Aug 7
Attenuation of bleomycin-induced pneumopathy in mice by monoclonal antibody to interleukin-12.
2001 Jun
An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents.
2002 Oct 15
Codon 64 of K-ras gene mutation pattern in hepatocellular carcinomas induced by bleomycin and 1-nitropyrene in A/J mice.
2003
CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis.
2003 Dec 21
Dual roles of IL-4 in lung injury and fibrosis.
2003 Feb 15
The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
2004 Dec
Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis.
2004 Dec
ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
2004 Jun
ROLE OF ENDOGENOUS AND EXOGENOUS LIGANDS FOR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR alpha IN THE DEVELOPMENT OF BLEOMYCIN-INDUCED LUNG INJURY.
2005 Dec
Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis.
2005 Dec
[Effects of valsartan on bleomycin-induced pulmonary fibrosis in rats and the expression of hepatocyte growth factor in lung tissue].
2005 Jul
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
2007 Aug 10
Are platinum-based chemotherapeutic drugs safe for patients with Charcot-Marie-Tooth disease?
2007 Jun
Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling.
2007 Jun 1
Effects of curcumin in treatment of experimental pulmonary fibrosis: a comparison with hydrocortisone.
2007 Jun 13
DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.
2008 Jan
Cerebellar dysfunction caused by procarbazine and consumption of excessive amount of bananas.
2008 Jun
Agents associated with lung inflammation induce similar responses in NCI-H292 lung epithelial cells.
2008 Oct
Radiation-induced cathepsin S is involved in radioresistance.
2009 Apr 15
Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats.
2010 Aug
C/EBPβ-Thr217 phosphorylation signaling contributes to the development of lung injury and fibrosis in mice.
2011
Anti-inflammatory and antifibrotic effects of methyl palmitate.
2011 Aug 1
Links between DNA polymerase beta expression and sensitivity to bleomycin.
2011 Mar 15
Removal of reactive oxygen species-induced 3'-blocked ends by XPF-ERCC1.
2011 Nov 21
The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals.
2012 Jan
Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis.
2013 Aug
Berberine attenuates bleomycin induced pulmonary toxicity and fibrosis via suppressing NF-κB dependant TGF-β activation: a biphasic experimental study.
2013 May 23
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Bleomycin can be given intramuscularly, or subcutaneously in Squamous cell carcinoma, non-Hodgkin’s lymphoma, testicular carcinoma, Hodgkin’s disease and as a single dose bolus intrapleural injection (60 units) in Malignant Pleural Effusion.
The main components of Bleomycin for Injection are bleomycins A2 and B2. Squamous cell carcinoma, non-Hodgkin’s lymphoma, testicular carcinoma - 0.25 to 0.50 units/kg (10 to 20 units/m2) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly.
Route of Administration: Other
In Vitro Use Guide
Purified nucleolar DNA was markedly degraded at a concentration of 13 ug/ml by bleomycin A2; bleomycin concentrations 20-30 times greater were required to degrade nucleoplasmic DNA. Whole nuclear DNA was degraded to only a small extent at 13 ug/ml but was markedly degraded at higher bleomycin concentrations.
Substance Class Mixture
Created
by admin
on Sat Jun 26 18:20:17 UTC 2021
Edited
by admin
on Sat Jun 26 18:20:17 UTC 2021
Record UNII
40S1VHN69B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BLEOMYCIN
HSDB   INN   VANDF   WHO-DD  
INN  
Official Name English
BLEOMYCIN HYDROCHLORIDE [JAN]
Common Name English
BLEOMYCIN [VANDF]
Common Name English
BLENAMAX
Brand Name English
NSC-125066
Code English
BLEOMYCINS
MI  
Common Name English
BLEOMYCIN [WHO-DD]
Common Name English
BLEOMYCIN [INN]
Common Name English
BLEOMYCINS [MI]
Common Name English
BLEOMYCIN [IARC]
Common Name English
BLEOMYCIN [HSDB]
Common Name English
BLEOMYCIN HEXAL
Brand Name English
BLEO
Brand Name English
BLEOCIN
Brand Name English
BLEOMYCINS [IARC]
Common Name English
MIXTURE OF CYTOTOXIC GLYCOPEPTIDES PRODUCED BY THE GROWTH OF STREPTOMYCES VERTICILLUS
Common Name English
Classification Tree Code System Code
LIVERTOX 116
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
WHO-VATC QL01DC01
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
NCI_THESAURUS C2311
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
NDF-RT N0000180854
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
FDA ORPHAN DRUG 118498
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
FDA ORPHAN DRUG 326510
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
WHO-ATC L01DC01
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
Code System Code Type Description
DRUG CENTRAL
4742
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
LACTMED
Bleomycin
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
RXCUI
1622
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY RxNorm
EVMPD
SUB00842MIG
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
HSDB
3208
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
ChEMBL
CHEMBL3039590
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
MESH
D001761
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
EPA CompTox
11056-06-7
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
CAS
11056-06-7
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
NCI_THESAURUS
C313
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
FDA UNII
40S1VHN69B
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
MERCK INDEX
M2589
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB00290
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
WIKIPEDIA
BLEOMYCIN
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
INN
2721
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
All of the following components must be present:
Related Record Type Details
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Definition References